Thrombus Articles & Analysis: Older
8 articles found
Existing devices can remove fresh thrombus but have difficulty creating a larger lumen through more organised material on the vessel wall,” says Black. ...
In the treatment of thrombophlebitis, myocardial infarction, pulmonary infarction and diffuse intravascular coagulation, plasmin, streptokinase, urokinase, etc. can be applied to dissolve blood clots and prevent the formation of thrombus. Some compound natural enzymes, based on high-unit SOD enzymes, can not only be used for the adjuvant treatment of important organs such as ...
The evolution of these therapies accelerated with the understanding that STEMI is caused by occlusive thrombus compromising flow in an epicardial coronary artery1,2. Initially, drug-based dissolution of the occlusive thrombus was the only therapeutic modality, but this has been superseded by mechanical recanalization and breakdown with wires and balloons with ...
The products include orthodontic wires, roots Tube file, spinal orthopedic rod, bone plate (nitinol sheet), intramedullary needle, patella claw, guidewire, guide needle, heart patch, vascular stent, thrombus filter, esophageal stent, respiratory tract stent, biliary stent, urethral stent, rectal stent, twelve Digital stents, external auditory canal stent, birth control ring, etc. ...
In the treatment of myocardial infarction, thrombophlebitis, pulmonary infarction and disseminated intravascular coagulation, streptokinase, plasmin, urokinase, etc. can be used to dissolve blood clots and prevent the formation of thrombus. Enzymes play a great role in medicine. Some coenzymes, such as coenzyme A and coenzyme Q, can be used for adjuvant therapy of important ...
New technology like the BASHIR Endovascular Catheters, which are capable of reducing significant thrombus burden with a small caliber device, may have a very positive role to play in improving long term quality of life. ...
The BEC is a pharmacomechanical device designed to enhance thrombolysis by increasing the exposure of thrombus to endogenous and exogenous thrombolytics. In Circulation: Cardiovascular Interventions, the investigators concluded, “In this early feasibility study of the BEC for intermediate - risk PE, there were no deaths or device-related adverse events and a significant ...
Alternative, advanced catheter-directed therapies that could provide more complete resolution of the thrombus burden have the potential to have a positive impact in reducing the incidence of these longer-term negative side effects. ...